142 related articles for article (PubMed ID: 37927219)
41. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract][Full Text] [Related]
42. Successful rechallenge therapy for BRAF/MEK inhibitor-resistant multiple brain metastases of melanoma.
Fukushima H; Iwata Y; Saito K; Sugiura K
J Dermatol; 2021 Aug; 48(8):1291-1295. PubMed ID: 34018641
[TBL] [Abstract][Full Text] [Related]
43. BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors.
Sasaki-Saito N; Yamamura K; Hitaka T; Hirano Y; Nishihara K; Aoki M; Matsushita S
J Dermatol; 2023 Jan; 50(1):e28-e29. PubMed ID: 36217799
[No Abstract] [Full Text] [Related]
44. BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports.
Melin A; Routier E; Tissot H; Rouleau E; Robert C
Eur J Cancer; 2019 Nov; 121():109-112. PubMed ID: 31569065
[No Abstract] [Full Text] [Related]
45. Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.
Mason R; Dearden HC; Nguyen B; Soon JA; Smith JL; Randhawa M; Mant A; Warburton L; Lo S; Meniawy T; Guminski A; Parente P; Ali S; Haydon A; Long GV; Carlino MS; Millward M; Atkinson VG; Menzies AM
Pigment Cell Melanoma Res; 2020 Mar; 33(2):358-365. PubMed ID: 31587511
[TBL] [Abstract][Full Text] [Related]
46. BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials.
Fujimura T; Hidaka T; Kambayashi Y; Aiba S
Expert Opin Investig Drugs; 2019 Feb; 28(2):143-148. PubMed ID: 30556435
[TBL] [Abstract][Full Text] [Related]
47. A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
Russo I; Zorzetto L; Frigo AC; Chiarion Sileni V; Alaibac M
Eur J Dermatol; 2017 Oct; 27(5):482-486. PubMed ID: 29084636
[TBL] [Abstract][Full Text] [Related]
48. Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma.
Buchacher L; Richtig G; Dernoscheg M; Richtig E; Koch L
J Eur Acad Dermatol Venereol; 2023 May; 37(5):e605-e607. PubMed ID: 36645848
[No Abstract] [Full Text] [Related]
49. Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis.
Pala L; De Pas T; Pagan E; Minucci S; Catania C; Digiacomo N; Cocorocchio E; Laszlo D; Di Muzio A; Barigazzi C; Stucchi E; De Grandi L; Stucchi S; Viale G; Gelber RD; Bagnardi V; Conforti F
Semin Oncol; 2023; 50(1-2):34-39. PubMed ID: 36967333
[TBL] [Abstract][Full Text] [Related]
50. Panniculitis in patients treated with BRAF/MEK inhibitors: Presentation of 4 new cases.
Cordeiro González P; Taibo Martínez A; Peña Penabad C
Med Clin (Barc); 2022 Jun; 158(11):e8-e9. PubMed ID: 34996624
[No Abstract] [Full Text] [Related]
51. Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma.
Eroglu Z; Chen YA; Smalley I; Li J; Markowitz JK; Brohl AS; Tetteh L; Taylor H; Sondak VK; Khushalani NI; Smalley KSM
Cancer; 2024 Jan; 130(2):232-243. PubMed ID: 37776537
[TBL] [Abstract][Full Text] [Related]
52. An approach to suppress the evolution of resistance in BRAF
Xue Y; Martelotto L; Baslan T; Vides A; Solomon M; Mai TT; Chaudhary N; Riely GJ; Li BT; Scott K; Cechhi F; Stierner U; Chadalavada K; de Stanchina E; Schwartz S; Hembrough T; Nanjangud G; Berger MF; Nilsson J; Lowe SW; Reis-Filho JS; Rosen N; Lito P
Nat Med; 2017 Aug; 23(8):929-937. PubMed ID: 28714990
[TBL] [Abstract][Full Text] [Related]
53. Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting.
Pedersen S; Larsen KO; Christensen AH; Svane IM; Zerahn B; Ellebaek E
Acta Oncol; 2022 Jan; 61(1):45-51. PubMed ID: 34666597
[TBL] [Abstract][Full Text] [Related]
54. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract][Full Text] [Related]
55. [Melanoma].
Uhara H
Gan To Kagaku Ryoho; 2016 Apr; 43(4):404-7. PubMed ID: 27220785
[TBL] [Abstract][Full Text] [Related]
56. A Japanese case of melanoma of unknown origin with a rare BRAF
Kuriyama H; Kimura T; Mizuhashi S; Nishimura Y; Kanemaru H; Kajihara I; Makino K; Aoi J; Matsui H; Fukushima S
Drug Discov Ther; 2022 Nov; 16(5):256-257. PubMed ID: 36273892
[TBL] [Abstract][Full Text] [Related]
57. [Treatment combinations in BRAF-mutant metastatic melanoma.].
Depenni R
Recenti Prog Med; 2021 Apr; 112(4):40e-43e. PubMed ID: 33877098
[TBL] [Abstract][Full Text] [Related]
58. [BRAF inhibitor and MEK inhibitor].
Uhara H
Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
[No Abstract] [Full Text] [Related]
59. MAPK blockade, toxicities, pathogenesis and management.
Moreira A; Lebbé C; Heinzerling L
Curr Opin Oncol; 2021 Mar; 33(2):139-145. PubMed ID: 33395033
[TBL] [Abstract][Full Text] [Related]
60. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Guha A; Jain P; Fradley MG; Lenihan D; Gutierrez JM; Jain C; de Lima M; Barnholtz-Sloan JS; Oliveira GH; Dowlati A; Al-Kindi S
Cancer Med; 2021 Jun; 10(12):3862-3872. PubMed ID: 33982883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
